Equities

Adiuvo Investments SA

0RKN:LSE

Adiuvo Investments SA

Actions
  • Price (PLN)--
  • Today's Change--
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 20 minutes.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Adiuvo Investments SA is a Poland-based company engaged in the financial industry. The Company focuses on the selection, development, financing and commercialization of biomedical projects on the international market. By providing intellectual property protection, technology validation in clinical trials and obtaining certificates allowing products to market, Adiuvo Investments SA is able to commercialize projects in diverse business model and internationally. The Company is looking for and invests in projects in the segments of the nutraceutical, medical devices and the digital health. Its business portfolio encompasses Airway Medix, Algae Labs, Carocelle, Cambridge Chocolate Technology, Endomedical, Esthechoc, Glia, Joint Polish Investment Fund, Marmar Investment, Nanoxide and Peptaderm.

  • Revenue in PLN (TTM)1.24m
  • Net income in PLN-10.28m
  • Incorporated2012
  • Employees8.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.